December 8th 2021, 10:52pm
A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.
December 8th 2021, 10:14pm
Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.
December 8th 2021, 9:45pm
Alexandra S. Zimmer, MD, discusses treatment options for patients with HER2-positive breast cancer who have developed brain metastasis.
December 8th 2021, 6:44pm
Data presented at the San Antonio Breast Cancer Sympsium found that in patients with a low HER2 immunohistochemistry (IHC) score of 0 or 1+, poor agreement in the evaluation of these patients exist using standard HER2 assays.
December 8th 2021, 5:34pm
Patients with higher Oncotype DX scores are more likely to complete the recommended 5 years of endocrine therapy.
December 7th 2021, 10:32pm
Early results from a phase 1 study show promise for datopotamab deruxtecan for patients with advanced or metastatic triple-negative breast cancer.
December 7th 2021, 10:18pm
Results from prespecified subgroup analyses of the phase KEYNOTE-522 study were presented during 2021 SABCS.
December 7th 2021, 9:53pm
Final results from the phase 3 PALLAS study show the addition of palbociclib to endocrine therapy lacks benefit for patients with early hormone receptor-positive, HER2-negative breast cancer.
December 7th 2021, 9:41pm
Updated results from the phase 3 3KEYNOTE-355 trial indicate a new standard of care for patients with metastatic triple-negative breast cancer in patients with a PD-L1 combined positive score of 10 or higher.
December 7th 2021, 7:10pm
Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.